Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (391-400 of 1,058) with videos related to

Pageof 106
Sort By:
Gastroenterology|July 25, 1998
Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3R S Bresalier, N Mazurek, L R Sternberg, et al.
Frontiers in Oncology|December 3, 2021
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical PracticeSusan M O'Brien, Jennifer R Brown, John C Byrd, et al.
American Journal of Pharmaceutical Education|June 22, 2019
Student Pharmacists' Personal Finance Perceptions, Projected Indebtedness Upon Graduation, and Career Decision-makingNicholas E Hagemeier, Chad K Gentry, Debbie C Byrd, et al.
Blood|October 1, 2008
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13Todd A Fehniger, John C Byrd, Guido Marcucci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessM S Czuczman, J P Leonard, S Jung, et al.
American Journal of Hematology|July 9, 2016
A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemiaIan W Flinn, Amy S Ruppert, William Harwin, et al.
Experimental Hematology|May 30, 2001
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanismJ C Byrd, C Shinn, C R Willis, et al.
Gastroenterology|May 1, 1996
Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasisR S Bresalier, S B Ho, H L Schoeppner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessM S Czuczman, J P Leonard, S Jung, et al.
Leukemia & Lymphoma|September 19, 2017
Role and regulation of microRNAs targeting BTK in acute myelogenous leukemiaLara Rizzotto, Tzung-Huei Lai, Arianna Bottoni, et al.
Pageof 106

Showing results (391-400 of 1,058) with videos related to

Sort By:
Pageof 106
Gastroenterology|July 25, 1998
Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3R S Bresalier, N Mazurek, L R Sternberg, et al.
Frontiers in Oncology|December 3, 2021
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical PracticeSusan M O'Brien, Jennifer R Brown, John C Byrd, et al.
American Journal of Pharmaceutical Education|June 22, 2019
Student Pharmacists' Personal Finance Perceptions, Projected Indebtedness Upon Graduation, and Career Decision-makingNicholas E Hagemeier, Chad K Gentry, Debbie C Byrd, et al.
Blood|October 1, 2008
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13Todd A Fehniger, John C Byrd, Guido Marcucci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessM S Czuczman, J P Leonard, S Jung, et al.
American Journal of Hematology|July 9, 2016
A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemiaIan W Flinn, Amy S Ruppert, William Harwin, et al.
Experimental Hematology|May 30, 2001
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanismJ C Byrd, C Shinn, C R Willis, et al.
Gastroenterology|May 1, 1996
Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasisR S Bresalier, S B Ho, H L Schoeppner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2018
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsivenessM S Czuczman, J P Leonard, S Jung, et al.
Leukemia & Lymphoma|September 19, 2017
Role and regulation of microRNAs targeting BTK in acute myelogenous leukemiaLara Rizzotto, Tzung-Huei Lai, Arianna Bottoni, et al.
Pageof 106